PT  - JOURNAL ARTICLE
AU  - RALPH MILLETT
AU  - ANITA AGGARWAL
AU  - IMAD TABBARA
AU  - SAMAH NASSEREDDINE
TI  - Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series
AID  - 10.21873/anticanres.13600
DP  - 2019 Aug 01
TA  - Anticancer Research
PG  - 4333--4335
VI  - 39
IP  - 8
4099  - http://ar.iiarjournals.org/content/39/8/4333.short
4100  - http://ar.iiarjournals.org/content/39/8/4333.full
SO  - Anticancer Res2019 Aug 01; 39
AB  - Secondary malignancies are relatively common and clinically important phenomena following both chemotherapy and radiotherapy. The majority of these cases are acute leukemias, the occurrence of which have been thoroughly documented and studied. More rarely, chronic myeloid leukemias (CML) may arise subsequent to treatment of a primary malignancy. Literature review on such developments following treatment of Hodgkin's Lymphoma (HL) is scant. Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion.